UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 19, 2024

 

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

  

Nevada		000-53500			87-0622284
(State or other jurisdiction		(Commission File Number)			(I.R.S. Employer
of incorporation)					Identification Number)

 

211 E Osborn Road, Phoenix, AZ 85012

(Address of principal executive offices)

 

(480) 399-2822

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	CELZ	The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

On July 19, 2024, Creative Medical Technology Holdings, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) to consider and vote on proposals for (i) the election of the director nominees named in the definitive proxy statement (the “Proxy Statement”) for the Annual Meeting filed with the Securities and Exchange Commission on June 5, 2024 (“Proposal I”); (ii) the approval of the compensation of the Company’s named executive officers (“Proposal II”); and (iii) the ratification of the appointment of Haynie & Company to serve as the Company’s independent registered public accountants (“Proposal III”).  Each of the foregoing proposals is described in more detail in the Proxy Statement.  Stockholders holding an aggregate of 832,170 shares of common stock, representing 61.7% of the outstanding shares of the Company’s common stock as of the record date, and which constituted a quorum, were present in person or represented by proxy at the Annual Meeting.   The proposal described in the Proxy Statement to increase the authorized shares of common stock of the Company was withdrawn by management prior to the Annual Meeting and was not voted on.  The results of the voting at the Annual Meeting are presented below.

 

Proposal I - The five director nominees were all elected to the Board as follows:

 

Director		For				Withhold
Timothy Warbington			312,403				147,859
Donald Dickerson			338,694				121,568
Michael H. Finger			337,737				122,525
Susan Snow			311,531				148,731
Bruce S. Urdang, Esq.			337,685				122,577

 

Proposal II - The compensation of the Company’s named executive officers was approved as follows:

 

For				Against				Abstain				Broker Non-Votes
	217,019				227,926				15,317				371,908

 

Proposal III –The ratification of the appointment of Haynie & Company was approved as follows:

 

For

Against

Abstain

Broker Non-Votes

684,717

90,973

56,480

N/A

 

Item 9.01 Financial Statements and Exhibits.

 

(d)		Exhibits.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Creative Medical Technology Holdings, Inc.
Date: July 25, 2024	By:	/s/ Timothy Warbington
		Timothy Warbington, Chief Executive Officer

 

3